Effects of IAS in Men With Localized Biochemical Relapsed Prostate Cancer
Status:
Completed
Trial end date:
2012-09-06
Target enrollment:
Participant gender:
Summary
This study was a prospective analysis in men with localized prostate cancer who had rising
Prostate Specific Antigen (PSA) levels after definitive treatment with surgery or radiation.
Patients received Intermittent Androgen Suppression (IAS) in 9 month cycles until they became
metastatic, became castrate resistant, or withdrew from the study. Subjects were monitored
for time to development of Castration Resistant Prostate Cancer (CRPC) and overall survival.
They were also monitored for the impact of IAS on a variety of neuro-psychiatric assessments
and on bone density.